kicked off on Monday, with AbCellera Biologics Inc (NASDAQ: ABCL) stock price up 6.15% from the previous day of trading, before settling in for the closing price of $2.44. ABCL’s price has ranged from $2.11 to $4.75 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 376.38%. Meanwhile, its annual earnings per share averaged -10.53%. With a float of $223.58 million, this company’s outstanding shares have now reached $295.76 million.
Let’s determine the extent of company efficiency that accounts for 596 employees. In terms of profitability, gross margin is -188.19%, operating margin of -1091.65%, and the pretax margin is -695.0%.
AbCellera Biologics Inc (ABCL) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of AbCellera Biologics Inc is 24.97%, while institutional ownership is 37.07%.
AbCellera Biologics Inc (ABCL) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -10.53% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.14% during the next five years compared to -107.74% drop over the previous five years of trading.
AbCellera Biologics Inc (NASDAQ: ABCL) Trading Performance Indicators
Here are AbCellera Biologics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of AbCellera Biologics Inc (ABCL)
Looking closely at AbCellera Biologics Inc (NASDAQ: ABCL), its last 5-days average volume was 3.37 million, which is a drop from its year-to-date volume of 4.19 million. As of the previous 9 days, the stock’s Stochastic %D was 73.59%. Additionally, its Average True Range was 0.18.
During the past 100 days, AbCellera Biologics Inc’s (ABCL) raw stochastic average was set at 30.57%, which indicates a significant decrease from 97.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.55% in the past 14 days, which was lower than the 71.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.89, while its 200-day Moving Average is $2.85. However, in the short run, AbCellera Biologics Inc’s stock first resistance to watch stands at $2.64. Second resistance stands at $2.70. The third major resistance level sits at $2.79. If the price goes on to break the first support level at $2.49, it is likely to go to the next support level at $2.40. Now, if the price goes above the second support level, the third support stands at $2.34.
AbCellera Biologics Inc (NASDAQ: ABCL) Key Stats
With a market capitalization of 771.79 million, the company has a total of 297,988K Shares Outstanding. Currently, annual sales are 28,830 K while annual income is -162,860 K. The company’s previous quarter sales were 5,050 K while its latest quarter income was -34,210 K.
